Xencor, Inc. (XNCR) Q3 2024 10-Q Summary
Business Context and Reporting Period
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and serious diseases. This report covers the quarterly period ended September 30, 2024. The company operates primarily through licensing its proprietary Fc technologies and developing its own pipeline of XmAb drug candidates.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $10.7 million | $59.2 million | $40.5 million | $123.6 million |
| Net Loss (Attributable to Xencor) | $(45.1) million | $(24.3) million | $(179.1) million | $(107.0) million |
| Net Loss Per Share (Basic/Diluted) | $(0.71) | $(0.40) | $(2.87) | $(1.77) |
| Operating Expenses | $73.0 million | $77.4 million | $222.9 million | $228.7 million |
| Cash & Cash Equivalents | $29.0 million | $53.8 million (Dec 2023) | Total Liquidity (Cash + Marketable Securities): $754.7 million | |
| Debt (Current + Long-term) | $17.9 million | $20.9 million (Dec 2023) | Primarily related to sale of future royalties | |
| Accumulated Deficit | $(643.5) million | $(464.4) million (Dec 2023) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased significantly year-over-year due to the absence of large milestone payments recognized in Q3 2023 (specifically from Janssen, Gilead, and Omeros). Q3 2024 revenue was driven primarily by non-cash royalty revenue from Alexion (Ultomiris) and Incyte (Monjuvi).
- Increased Net Loss: The net loss widened to $45.1 million in Q3 2024 from $24.3 million in Q3 2023, reflecting lower revenues and continued investment in clinical programs.
- Equity Financing: In September 2024, the company completed an underwritten public offering, raising net proceeds of approximately $189.2 million through the sale of common stock and pre-funded warrants.
- Investment Impairment: The company recorded a $20.4 million impairment charge on equity securities (Zenas BioPharma) during the first half of 2024. Following Zenas' IPO in September 2024, the company recorded an unrealized gain of $8.6 million on the converted common stock.
- Partnership Changes: Johnson & Johnson terminated its rights to plamotamab in June 2024, allowing Xencor to regain exclusive worldwide rights to develop and commercialize the candidate.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, marketable securities, and potential milestone payments to fund operating expenses and capital expenditures into 2028.
- Clinical Pipeline Updates:
- XmAb819: Initial evidence of anti-tumor activity observed in Phase 1; dose escalation continuing.
- XmAb808: PSA declines observed in prostate cancer patients; dose-limiting toxicities noted in the highest cohort, prompting back-fill enrollment in a lower dose.
- Plamotamab: Plans to initiate a Phase 1b/2a proof-of-concept study in rheumatoid arthritis in the first half of 2025.
- XmAb942: First-in-human study initiated in Q4 2024; initial data expected in H1 2025.
- Legal Proceedings: Merus N.V. filed a patent infringement lawsuit in August 2024 alleging infringement of three patents related to common light chain and heterodimeric antibodies. Xencor has filed a motion to dismiss, citing the 35 U.S.C. § 271(e)(1) safe harbor, and believes it has strong defenses.
- Internal Controls: The company has remediated a previously reported material weakness regarding the impairment analysis of equity securities without a readily determinable fair value.
Investor Verification Checklist
- Verify the status and timeline of the Merus N.V. patent litigation and the potential impact on the commercialization of key candidates like plamotamab and vudalimab.
- Monitor the clinical data readouts for XmAb819, XmAb808, and vudalimab expected in 2025, which are critical for future valuation.
- Assess the sustainability of non-cash royalty revenue from Alexion and Incyte, which currently drives the majority of reported revenue.
- Review the burn rate relative to the $754.7 million liquidity position to confirm the runway into 2028.
- Track the progress of the regained plamotamab program in autoimmune indications following the J&J termination.